Study reveals lineage-specific bone marrow suppression by oxaliplatin, indicating potential risks for treatment.
This study reveals that oxaliplatin causes lineage-specific bone marrow suppression by disrupting cell cycle, cytokine signaling, and erythropoiesis, highlighting key molecular drivers of hematologic toxicity.
No takes yet. Share an insight, caveat, or question.
Leland et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: